Sign In
Buy INMB
$1.32
-0.1000 (-7.04%)
At Close: Jun 03, 2026
Dive Into the World of Cryptocurrencies and other Trading tools with TradeATF
02:35pm, Tuesday, 21'st Apr 2020
Trade CFDs on Indices, cryptocurrencies, metals, forex, stocks, and commodities on a single platform Choosing the right brokerage firm is as crucial as choosing trading assets. If your decision is rig
INmune Bio, Inc. (INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced the initiation of a therapeutic p
NantKwest In 'Active Discussions' With FDA On COVID-19 Vaccine, Therapeutic Development
12:00am, Tuesday, 14'th Apr 2020
Shares of small-cap immunotherapy company Nantkwest Inc (NASDAQ: NK), a leading producer of clinical dose forms of off-the-shelf natural killer cell therapies, were adding to...
Analysts Offer Insights on Healthcare Companies: Dynavax (DVAX), Proteostasis Therapeutics (PTI) and Inmune Bio (INMB)
11:14am, Thursday, 12'th Mar 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX), Proteostasis Therapeutics (PTI) and Inmune
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX
LA JOLLA, Calif., March 11, 2020 -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system.
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
08:14pm, Sunday, 08'th Mar 2020
Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.The week was light on news flow, barring some smid-cap earnings and COVID-19 treatment and vaccin
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
12:00am, Sunday, 08'th Mar 2020
Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.
The week was light on news flow, barring some smid-cap earnings and...
INmune Bio, Inc. to Present at the 32nd Annual ROTH Conference on March 17
02:00pm, Thursday, 05'th Mar 2020
INmune Bio, Inc., an immunology company developing treatments that harness the patient’s innate immune system to fight disease, today announced that management will present at the 32nd Annual Roth C
INmune Bio, Inc. Schedules Conference Call to Report 2019 Fourth Quarter and Full Year Financial Results
02:00pm, Thursday, 27'th Feb 2020
INmune Bio, Inc., an immunotherapy company developing therapies that reprogram the patient’s innate immune system to treat disease, today announced that it will release financial results for its 201
New hybrids and varieties give farmers more choice in 2021
10:28pm, Wednesday, 26'th Feb 2020
Whether it's unpredictable weather or the appearance of new pests and diseases, farming remains as challenging as ever. To help farmers minimize risk and maximize potential return on investment despit
INmune Bio (NASDAQ:INMB) versus BIO-TECHNE (NASDAQ:TECH) Head-To-Head Review
08:24am, Tuesday, 25'th Feb 2020
INmune Bio (NASDAQ:INMB) and BIO-TECHNE (NASDAQ:TECH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional owne
INmune Bio, Inc. (INMB), an immunology company developing treatments that reprogram the patient’s innate immune system to fight disease, today announced that it has been awarded a $500,000 grant fro
Have Insiders Been Buying INmune Bio Inc. (NASDAQ:INMB) Shares?
01:25pm, Wednesday, 29'th Jan 2020
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
INmune Bio, Inc. (INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced today the publication of new positive data in the jou
